Reduced toxicity conditioning approaches may be of particular interest in patients who have MDS due to underlying inherited marrow failure syndromes such as GATA2 deficiency that increase the risk for infection, or patients with treatment-associated MDS and a history of prior intensive chemotherapy. This evidence concerns the gene GATA2 and hyperinsulinemic hypoglycemia, familial, 4.